Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer

R. Phaëton, J. Gutierrez, Z. Jiang, Rouzan G. Karabakhtsian, J. Albanese, J. Sunkara, D. R. Fisher, G. L. Goldberg, E. Dadachova

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: In spite of profound reduction in incidence, cervical cancer claims >275,000 lives annually. Previously we demonstrated efficacy and safety of radioimmunotherapy directed at HPV16 E6 oncoprotein in experimental cervical cancer. Materials & methods: We undertook a direct comparison of targeting E7 and E6 oncoproteins with specific <sup>188</sup>Rhenium-labeled monoclonal antibodies in CasKi subcutaneous xenografts of cervical cancer cells in mice. Results: The most significant tumor inhibition was seen in radioimmunotherapy-treated mice, followed by the unlabeled monoclonal antibodies to E6 and E7. No hematological toxicity was observed. Immunohistochemistry suggests that the effect of unlabeled antibodies is C3 complement mediated. Conclusion: We have demonstrated for the first time that radioimmunotherapy directed toward E7 oncoprotein inhibits experimental tumors growth, decreases E7 expression and may offer a novel approach to cervical cancer therapy.

Original languageEnglish (US)
Pages (from-to)631-640
Number of pages10
JournalImmunotherapy
Volume7
Issue number6
DOIs
StatePublished - Jul 1 2015

Fingerprint

Human papillomavirus 16
Oncogene Proteins
Radioimmunotherapy
Uterine Cervical Neoplasms
Antibodies
Monoclonal Antibodies
Complement C3
Heterografts
Neoplasms
Immunohistochemistry
Safety
Incidence
Growth
Therapeutics

Keywords

  • <sup>188</sup>Rhenium
  • apoptosis
  • complement cytotoxicity
  • E6 and E7 oncoproteins
  • HPV16 positive cervical cancer
  • p53 expression
  • radioimmunotherapy
  • retinoblastoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer. / Phaëton, R.; Gutierrez, J.; Jiang, Z.; Karabakhtsian, Rouzan G.; Albanese, J.; Sunkara, J.; Fisher, D. R.; Goldberg, G. L.; Dadachova, E.

In: Immunotherapy, Vol. 7, No. 6, 01.07.2015, p. 631-640.

Research output: Contribution to journalArticle

Phaëton, R, Gutierrez, J, Jiang, Z, Karabakhtsian, RG, Albanese, J, Sunkara, J, Fisher, DR, Goldberg, GL & Dadachova, E 2015, 'Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer', Immunotherapy, vol. 7, no. 6, pp. 631-640. https://doi.org/10.2217/imt.15.18
Phaëton, R. ; Gutierrez, J. ; Jiang, Z. ; Karabakhtsian, Rouzan G. ; Albanese, J. ; Sunkara, J. ; Fisher, D. R. ; Goldberg, G. L. ; Dadachova, E. / Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer. In: Immunotherapy. 2015 ; Vol. 7, No. 6. pp. 631-640.
@article{f6dd11807d5b4133b353896fe0825e56,
title = "Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer",
abstract = "Background: In spite of profound reduction in incidence, cervical cancer claims >275,000 lives annually. Previously we demonstrated efficacy and safety of radioimmunotherapy directed at HPV16 E6 oncoprotein in experimental cervical cancer. Materials & methods: We undertook a direct comparison of targeting E7 and E6 oncoproteins with specific 188Rhenium-labeled monoclonal antibodies in CasKi subcutaneous xenografts of cervical cancer cells in mice. Results: The most significant tumor inhibition was seen in radioimmunotherapy-treated mice, followed by the unlabeled monoclonal antibodies to E6 and E7. No hematological toxicity was observed. Immunohistochemistry suggests that the effect of unlabeled antibodies is C3 complement mediated. Conclusion: We have demonstrated for the first time that radioimmunotherapy directed toward E7 oncoprotein inhibits experimental tumors growth, decreases E7 expression and may offer a novel approach to cervical cancer therapy.",
keywords = "<sup>188</sup>Rhenium, apoptosis, complement cytotoxicity, E6 and E7 oncoproteins, HPV16 positive cervical cancer, p53 expression, radioimmunotherapy, retinoblastoma",
author = "R. Pha{\"e}ton and J. Gutierrez and Z. Jiang and Karabakhtsian, {Rouzan G.} and J. Albanese and J. Sunkara and Fisher, {D. R.} and Goldberg, {G. L.} and E. Dadachova",
year = "2015",
month = "7",
day = "1",
doi = "10.2217/imt.15.18",
language = "English (US)",
volume = "7",
pages = "631--640",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer

AU - Phaëton, R.

AU - Gutierrez, J.

AU - Jiang, Z.

AU - Karabakhtsian, Rouzan G.

AU - Albanese, J.

AU - Sunkara, J.

AU - Fisher, D. R.

AU - Goldberg, G. L.

AU - Dadachova, E.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Background: In spite of profound reduction in incidence, cervical cancer claims >275,000 lives annually. Previously we demonstrated efficacy and safety of radioimmunotherapy directed at HPV16 E6 oncoprotein in experimental cervical cancer. Materials & methods: We undertook a direct comparison of targeting E7 and E6 oncoproteins with specific 188Rhenium-labeled monoclonal antibodies in CasKi subcutaneous xenografts of cervical cancer cells in mice. Results: The most significant tumor inhibition was seen in radioimmunotherapy-treated mice, followed by the unlabeled monoclonal antibodies to E6 and E7. No hematological toxicity was observed. Immunohistochemistry suggests that the effect of unlabeled antibodies is C3 complement mediated. Conclusion: We have demonstrated for the first time that radioimmunotherapy directed toward E7 oncoprotein inhibits experimental tumors growth, decreases E7 expression and may offer a novel approach to cervical cancer therapy.

AB - Background: In spite of profound reduction in incidence, cervical cancer claims >275,000 lives annually. Previously we demonstrated efficacy and safety of radioimmunotherapy directed at HPV16 E6 oncoprotein in experimental cervical cancer. Materials & methods: We undertook a direct comparison of targeting E7 and E6 oncoproteins with specific 188Rhenium-labeled monoclonal antibodies in CasKi subcutaneous xenografts of cervical cancer cells in mice. Results: The most significant tumor inhibition was seen in radioimmunotherapy-treated mice, followed by the unlabeled monoclonal antibodies to E6 and E7. No hematological toxicity was observed. Immunohistochemistry suggests that the effect of unlabeled antibodies is C3 complement mediated. Conclusion: We have demonstrated for the first time that radioimmunotherapy directed toward E7 oncoprotein inhibits experimental tumors growth, decreases E7 expression and may offer a novel approach to cervical cancer therapy.

KW - <sup>188</sup>Rhenium

KW - apoptosis

KW - complement cytotoxicity

KW - E6 and E7 oncoproteins

KW - HPV16 positive cervical cancer

KW - p53 expression

KW - radioimmunotherapy

KW - retinoblastoma

UR - http://www.scopus.com/inward/record.url?scp=84937719366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937719366&partnerID=8YFLogxK

U2 - 10.2217/imt.15.18

DO - 10.2217/imt.15.18

M3 - Article

C2 - 26098137

AN - SCOPUS:84937719366

VL - 7

SP - 631

EP - 640

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 6

ER -